Purchase of Own Shares & Buyback Prog. Completion
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Purchase of Own Shares
& Completion of Share Buyback Programme
EKF, the AIM-listed global diagnostics business, announces that it has purchased a further 200,000 of its ordinary shares at a price of 40 pence per share. The ordinary shares purchased will be held in treasury.
This transaction marks the successful conclusion of the share buyback programme as set out in the announcement on 29 March 2022. Under that programme, a total of 9,000,000 ordinary shares were purchased at an average cost of 43.29 pence per share. Buying back this amount of ordinary shares at current levels more than offsets the dilutive effect of the new ordinary shares issued in 2021.
Aggregated information related to the most recent Purchase of Own Shares
|
Date of purchase |
8 April 2022 |
|
Number of ordinary shares purchased |
200,000 |
|
Highest price paid per share |
40 |
|
Lowest price paid per share |
40 |
|
Volume weighted average price paid |
40 |
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) , a detailed breakdown of individual trades is available below:
|
Number of ordinary shares purchased |
Transaction price (GBp) |
Time of transaction |
Trading venue |
|
200,000 |
40 |
08:24:00 |
AIMX |
Total voting rights
Following the purchase, the Company's total issued share capital will consist of 463,930,564 ordinary shares of 1 pence each ("Ordinary Shares") each carrying one voting right, of which 9,000,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 454,930,564. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
EKF Diagnostics Holdings plc | ||
Mike Salter, CEO | Tel: +44 (0)29 2071 0570 | |
Marc Davies, CFO |
| |
|
| |
Singer Capital Markets (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7496 3000 | |
Aubrey Powell / George Tzimas / Tom Salvesen |
| |
|
| |
Investec Bank plc (Joint Broker) | Tel: +44 (0)20 7597 4000 | |
Gary Clarence / Daniel Adams / Ben Farrow |
| |
|
| |
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 orekf@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 | |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
Point-of-Care | Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
|
Central Laboratory | Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
|
Life Sciences | Enzyme fermentation, Custom products and Bulk fermentation
|
Contract Manufacturing | Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
|
Laboratory Services | In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results. |
In May 2021, EKF announced its strategy for delivering growth to 2024 and beyond, and continuing to deliver shareholder value. The strategy for growth can be summarised as:
• | continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships; |
• | investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses; |
• | expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and |
• | identify complementary earnings-enhancing acquisitions with key strategic value. |
EKF will also continue to generate enhanced shareholder value through:
• | a progressive dividend policy; and |
• | its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 13 hours ago Johnson Matthey
- 14 hours ago Galliford Try
- 14 hours ago Galliford Try
- 14 hours ago Centrica
- 15 hours ago Smith & Nephew